Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016987 | 0.88 | USP2 (0.42) | SMN1; SMN2HDAC3ALDH1A1KMT2ALMNA | |
| SCHEMBL155927 | 0.84 | HDAC3 (0.44) | HDAC3KMT2AHDAC1SMYD3CRBN | |
| SCHEMBL152807 | 0.82 | HDAC3 (0.45) | HDAC3HDAC1SMYD3CRBN | |
| SCHEMBL154464 | 0.78 | HDAC3 (0.45) | HDAC3HDAC1SMYD3CRBN | |
| SCHEMBL155351 | 0.78 | HDAC3 (0.42) | HDAC3HDAC1PARP1SMYD3CRBN | |
| SCHEMBL154463 | 0.78 | HDAC3 (0.45) | HDAC3HDAC1SMYD3CRBN | |
| SCHEMBL155039 | 0.78 | SMYD3 (0.53) | SMN1; SMN2HDAC3ALDH1A1HTTHDAC1 | |
| SCHEMBL25567414 | 0.77 | HDAC3 (0.41) | SMN1; SMN2HDAC3KMT2ALMNAPARP1 | |
| SCHEMBL13449528 | 0.76 | HDAC3 (0.43) | HDAC3HDAC1SMYD3CRBN | |
| SCHEMBL155059 | 0.76 | HDAC3 (0.41) | HDAC3SMYD3CRBNGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697692-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-04-15 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| EP-1973910-B1 | PYRROLO[3,2-C]PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2013-06-26 | — | — | EP | disclosed |
| US-8362251-B2 | Pyrrolo [3,2-C] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-01-29 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8299069-B2 | 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1H-pyrrol[3,2-C]pyridine-4(5H)-one compounds and use as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2012-10-30 | — | — | US | disclosed |
| EP-2179998-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179998-A1 | 2-(2-OXOINDOLINE-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YL -PROPYL)-6,7-DIHYDRO -1H- PYRROL[3,2-C]PYRIDINE-4(5H)-ONE COMPOUNDS AND USE AS PROTEIN KINASE INHIBITORS | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-04-28 | — | — | EP | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | SMN1; SMN2 4172/4885HDAC3 1925/4885ALDH1A1 2707/4885 |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | PRKACA, PACSIN2, PRKACB | SMN1; SMN2 468/4885HDAC3 2871/4885ALDH1A1 4203/4885 |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | DMPK, CDK2, PRKAR2A | SMN1; SMN2 4148/4885HDAC3 1756/4885ALDH1A1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.